SHARE:

December 13, 2016 E-Pearl of the Week: Aquaporin-4 antibody-negative neuromyelitis optica

Interested in submitting an E-Pearl?
Brought to you by the Residents & Fellows Section of Neurology®.

December 13, 2016

Aquaporin-4 antibody-negative neuromyelitis optica

Neuromyelitis optica (NMO) is an aggressive inflammatory neurologic disease associated with optic neuritis and longitudinally extensive cord lesions. Serologic testing for aquaporin-4 IgG (AQP4) antibodies is only 80% sensitive. In AQP4-negative cases, anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibodies are observed 10-20% of the time. Compared to patients with AQP4 antibodies, those with anti-MOG are younger, less commonly female (2:1 M:F vs. 1:9 in AQP4 disease), and almost never relapse. In patients without AQP4 antibodies, anti-MOG testing should be performed as it heralds a more benign prognosis.

References

  1. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between mog antibody-positive and aqp4 antibody-positive nmo spectrum disorders. Neurology. 2014; 82: 474-481.

James E. Siegler III, MD, Resident Physician - Department of Neurology, Hospital of the University of Pennsylvania. Dr. Siegler is a member of the Resident and Fellow Section of Neurology

For more clinical pearls and other articles of interest to neurology trainees, visit Neurology® .

Click here to visit the E-Pearl of the Week archive.

Listen to this week's Neurology Podcast

 

 

MEMBER LOG IN

Forgot password?

**Due to required system maintenance on AAN.com, some functions may be unavailable Saturday from 1:00 p.m. to 6:00 p.m. Saturday (12/9/2017). Thank you for your patience.**

Advertisement